RT Journal Article
SR Electronic
T1 Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.08.22272062
DO 10.1101/2022.03.08.22272062
A1 Kaabi, Nawal Al
A1 Yang, Yun Kai
A1 Du, Li Fang
A1 Xu, Ke
A1 Shao, Shuai
A1 Liang, Yu
A1 Kang, Yun
A1 Su, Ji Guo
A1 Zhang, Jing
A1 Yang, Tian
A1 Hussein, Salah
A1 ElDein, Mohamed Saif
A1 Yang, Sen Sen
A1 Lei, Wenwen
A1 Gao, Xue Jun
A1 Jiang, Zhiwei
A1 Cong, Xiangfeng
A1 Tan, Yao
A1 Wang, Hui
A1 Li, Meng
A1 Mekki, Hanadi Mekki
A1 Zaher, Walid
A1 Mahmoud, Sally
A1 Zhang, Xue
A1 Qu, Chang
A1 Liu, Dan Ying
A1 Zhang, Jing
A1 Yang, Mengjie
A1 Eltantawy, Islam
A1 Hou, Jun Wei
A1 Lei, Ze Hua
A1 Xiao, Peng
A1 Wang, Zhao Nian
A1 Yin, Jin Liang
A1 Mao, Xiao Yan
A1 Zhang, Jin
A1 Qu, Liang
A1 Zhang, Yun Tao
A1 Yang, Xiao Ming
A1 Wu, Guizhen
A1 Li, Qi Ming
YR 2022
UL http://medrxiv.org/content/early/2022/03/10/2022.03.08.22272062.abstract
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with immune escape ability raises the urgent need for developing cross-neutralizing vaccines against the virus. NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen. Here, we evaluated the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in adults previously vaccinated with the inactivated vaccine BBIBP-CorV in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates (NCT05069129). Three groups of healthy adults over 18 years of age (600 participants per group) who had administered two doses of BBIBP-CorV 4-6-month, 7-9-month and >9-month earlier, respectively, were vaccinated with either a homologous booster of BBIBP-CorV or a heterologous booster of NVSI-06-08. The primary outcome was immunogenicity and safety of booster vaccinations. The exploratory outcome was cross-reactive immunogenicity against multiple SARS-CoV-2 variants of concerns (VOCs). The incidence of adverse reactions was low in both booster vaccinations, and the overall safety profile of heterologous boost was quite similar to that of homologous boost. Heterologous NVSI-06-08 booster was immunogenically superior to homologous booster of BBIBP-CorV. Both Neutralizing and IgG antibodies elicited by NVSI-06-08 booster were significantly higher than by the booster of BBIBP-CorV against not only SARS-CoV-2 prototype strain but also multiple VOCs. Especially, the neutralizing activity induced by NVSI-06-08 booster against the immune-evasive Beta variant was no less than that against the prototype strain, and a considerable level of neutralizing antibodies against Omicron (GMT: 367.67; 95%CI, 295.50-457.47) was induced by heterologous booster, which was substantially higher than that boosted by BBIBP-CorV (GMT: 45.03; 95%CI, 36.37-55.74). Our findings showed that NVSI-06-08 was safe and immunogenic as a booster dose following two doses of BBIBP-CorV, which was immunogenically superior to homologous boost with another dose of BBIBP-CorV. Our study also indicated that the design of hybrid antigen may provide an effective strategy for broad-spectrum vaccine developments.Competing Interest StatementY.K.Y., T.Y., M.L., X.Z., C.Q., D.Y.L., Z.N.W., J.L.Y., L.Q., Y.T.Z. and X.M.Y. are employees of the China National Biotec Group Company Limited. L.F.D., S.S., Y.L., Y.K., J.G.S., JingZ.(NVSI), S.S.Y., X.C., Y.T., J.W.H., Z.H.L. and Q.M.L. are employees of the National Vaccine and Serum Institute (NVSI). X.J.G. and X.Y.M. are employees of Lanzhou Institute of Biological Products Company Limited (LIBP). H.W. and JinZhang are employees of Beijing Institute of Biological Products Company Limited (BIBP). L.F.D., S.S., Y.L., J.G.S., JingZ.(NVSI), J.W.H., Z.H.L. and Q.M.L. are listed as inventors of the patent applications for the recombinant trimeric RBD-based vaccines (Application numbers: 202110348881.6, 202110464788.1 and 202110676901.2). The other authors declare no competing interests.Clinical TrialNCT05069129Funding StatementThe study was funded by Lanzhou Institute of Biological Products Co., Ltd (LIBP) of Sinopharm and Beijing Institute of Biological Products Co., Ltd (BIBP) of Sinopharm.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Abu Dhabi Health Research and Technology Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe clinical trial is still ongoing, and the data will be available when the trial is complete upon request to the corresponding author Qi Ming Li (liqiming189@163.com). After proposals are approved, data can be shared through secure online platforms.